<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639246</url>
  </required_header>
  <id_info>
    <org_study_id>AVB500-OC-002</org_study_id>
    <nct_id>NCT03639246</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aravive, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aravive, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin
      (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. The
      phase 1b portion of the study is open label and patients will receive either AVB-S6-500+PLD
      or AVB-S6-500+ Pac. The Phase 2 portion of the study is randomized, double-blind,
      placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination
      with PLD or Pac versus placebo plus PLD or Pac.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by the number of patients with AEs in Phase 1 portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of AVB-S6-500 in combination with PLD</measure>
    <time_frame>18 months</time_frame>
    <description>Measured by progression free survival (PFS) in patients receiving AVB-S6-500+PLD versus patients receiving Placebo+PLD in Phase 2 portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of AVB-S6-500 in combination with Pac</measure>
    <time_frame>18 months</time_frame>
    <description>Measured by progression free survival (PFS) in patients receiving AVB-S6-500+ Pac versus patients receiving Placebo+Pac in Phase 2 portion of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC</measure>
    <time_frame>18 months</time_frame>
    <description>Area under the AVB-S6-500 concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>18 months</time_frame>
    <description>Maximum observed AVB-S6-500 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax</measure>
    <time_frame>18 months</time_frame>
    <description>Time of maximum observed AVB-S6-500 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: t1/2</measure>
    <time_frame>18 months</time_frame>
    <description>Apparent terminal half-life of AVB-S6-500.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic marker assessment</measure>
    <time_frame>18 months</time_frame>
    <description>Change from the baseline in GAS6 serum levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) titers</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in ADA titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of subjects who have a partial or complete response to therapy relative to baseline as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as well as Gynecologic Cancer Intergroup (GCIG) cancer antigen (CA)-125 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of subjects who have a complete or partial response to therapy or maintain stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>18 months</time_frame>
    <description>Measured from the date of partial or complete response to therapy until the cancer progresses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>30 months</time_frame>
    <description>Time following the treatment until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 response rate</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of subjects with a minimum 50% reduction in CA-125 serum levels lasting for 28 days relative to baseline CA-125 serum levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life(QOL)</measure>
    <time_frame>18 months</time_frame>
    <description>Subject QOL will be assessed every 8 weeks during treatment using the Functional Assessment Of Cancer Therapy - Ovarian Cancer (FACT-O) questionnaire, which consists of 4 subscales: physical well-being (7 questions), social/family well-being (7 questions), emotional well-being (6 questions), and functional well-being (7 questions), and 12 additional concerns specific to ovarian cancer. All items are rated on a 5 point scale with 0 &quot;not at all&quot; and 4 &quot;very much&quot;. The scoring algorithm allows for eight summary scales: the four core well-being subscales, a subtotal of the 27 core items, a subtotal of the 12 ovarian-specific additional concerns, a grand total of the 39 items, and a trial outcome index (sum of the 17 physical and functional wellbeing items plus the 12 ovarian-specific items).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b: AVB-S6-500+PLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: AVB-S6-500+Pac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: AVB-S6-500+PLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: AVB-S6-500+Pac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Placebo+PLD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Placebo+Pac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVB-S6-500</intervention_name>
    <description>AVB-S6-500 is experimental drug</description>
    <arm_group_label>Phase 1b: AVB-S6-500+PLD</arm_group_label>
    <arm_group_label>Phase 1b: AVB-S6-500+Pac</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+PLD</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+Pac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel (Pac)</intervention_name>
    <description>Paclitaxel is active comparator</description>
    <arm_group_label>Phase 1b: AVB-S6-500+Pac</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+Pac</arm_group_label>
    <arm_group_label>Phase 2: Placebo+Pac</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>PLD is active comparator</description>
    <arm_group_label>Phase 1b: AVB-S6-500+PLD</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+PLD</arm_group_label>
    <arm_group_label>Phase 2: Placebo+PLD</arm_group_label>
    <other_name>Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Phase 2: Placebo+PLD</arm_group_label>
    <arm_group_label>Phase 2: Placebo+Pac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Histologically confirmed and documented recurrent ovarian, fallopian tube, and
             peritoneal cancer.

          -  Platinum resistant disease, defined as progression within ≤ 6 months from completion
             of most recent regimen and calculated from the date of the last administered dose of
             platinum therapy

          -  Must have available archived tumor tissue OR if archived tissue is not available,
             willing to provide a fresh tumor biopsy

          -  Must have radiologic imaging with a computerized tomography (CT) scan or magnetic
             resonance imaging (MRI) within 4 weeks of first dose of study drug

          -  Received at least 1 but not more than 3 therapy regimens, not including maintenance or
             adjuvant therapy

          -  Must have ovarian cancer that is measurable according to RECIST 1.1

          -  ECOG performance status of 0-1

          -  Normal gastrointestinal (GI), bone marrow, liver and kidney function

          -  At least 28 days between termination of prior anti-cancer or hormonal therapy and
             administration of AVB-S6-500

        Exclusion Criteria:

          -  Primary platinum-refractory disease (defined as progression during the first platinum
             regimen or within 4 weeks of completion of the first platinum regimen)

          -  Currently being treated with concurrent anti-cancer therapy or any other
             interventional treatment or trial

          -  Received prior therapy with Pac or PLD in the recurrent setting, depending on
             physician-chosen chemotherapy for this study

          -  Significant cardiac disease history

          -  Has other prior or concurrent malignancy within the past 5 years except adequately
             treated basal cell skin cancer or carcinoma in situ of the cervix

          -  Symptomatic CNS metastasis or metastases

          -  Serious active infection requiring IV antibiotics and/or hospitalization at study
             entry

          -  Has known previous or current human immune deficiency (HIV) syndrome, hepatitis B, or
             hepatitis C

          -  Has had paracentesis for ascites within 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Jo Baker</last_name>
    <role>Study Director</role>
    <affiliation>Aravive Biologics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aravive Clinical Trials</last_name>
    <phone>936-355-1910</phone>
    <email>clinicaltrials@aravive.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Perry</last_name>
      <phone>281-863-6507</phone>
      <email>tiffany.perry@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Perry</last_name>
      <phone>281-863-6507</phone>
      <email>tiffany.perry@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Jose</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Leandro</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente South San Francisco</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Walnut Creek</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Drake</last_name>
      <phone>314-747-3678</phone>
      <email>sarahdrake@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OUHSC-Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Perry</last_name>
      <phone>281-863-6507</phone>
      <email>tiffany.perry@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Perry</last_name>
      <phone>281-863-6507</phone>
      <email>tiffany.perry@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Perry</last_name>
      <phone>281-863-6507</phone>
      <email>tiffany.perry@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Perry</last_name>
      <phone>281-863-6507</phone>
      <email>tiffany.perry@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Perry</last_name>
      <phone>281-863-6507</phone>
      <email>tiffany.perry@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Perry</last_name>
      <phone>281-863-6507</phone>
      <email>tiffany.perry@mckesson.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Platinum resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

